Pepcid Ac

Zollinger-Ellison Syndrome, Curling Ulcer, Indigestion + 21 more

Treatment

4 FDA approvals

20 Active Studies for Pepcid Ac

What is Pepcid Ac

Famotidine

The Generic name of this drug

Treatment Summary

Famotidine is a drug used to reduce the amount of acid in the stomach. It is commonly prescribed for gastrointestinal conditions related to excess acid, such as gastric ulcers and GERD, in both adults and children. Compared to other acid-reducing drugs, famotidine is more selective and potent. It is available in both oral and intravenous formulations and can be used both as a prescription drug and over-the-counter.

Pepcid

is the brand name

image of different drug pills on a surface

Pepcid Ac Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Pepcid

Famotidine

1986

623

Approved as Treatment by the FDA

Famotidine, also called Pepcid, is approved by the FDA for 4 uses which include Heartburn and Heartburn .

Heartburn

Heartburn

prophylaxis of Heartburn

Heartburn

Effectiveness

How Pepcid Ac Affects Patients

Famotidine helps to reduce the amount of acid in your stomach. It works quickly, with effects typically seen within an hour, and can last up to 12 hours. It is most effective when taken at the highest dose. Famotidine also reduces the amount of pepsin in the stomach, and blocks acid secretion triggered by food, caffeine, insulin, or pentagastrin.

How Pepcid Ac works in the body

Histamine is a hormone that helps control the acid production of your stomach. It is released by special cells near your parietal cells, and is also triggered by acetylcholine and gastrin. Gastrin works on CCK2 receptors to cause the release of even more histamine. When histamine is released, it acts on H2 receptors and causes more acid to be produced. Famotidine works by blocking the effects of histamine, reducing the amount of acid produced in your stomach. This can help reduce symptoms of conditions that involve too much acid production, like ulcers.

When to interrupt dosage

The advised dosage of Pepcid Ac is contingent upon the diagnosed condition, including Heartburn, Heartburn and Pathological Conditions, Anatomical. The amount of dosage fluctuates in accordance with the delivery technique (e.g. Tablet, film coated - Oral or Oral) featured in the following table.

Condition

Dosage

Administration

Heartburn

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Collagen Diseases

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Heartburn

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Erosive Esophagitis

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Obesity

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Zollinger-Ellison Syndrome

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Stress Ulcers

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Pain

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Gastric ulcer

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Multiple Endocrine Neoplasia

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Critical Illness

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Spasm

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Pathological Conditions, Anatomical

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Helicobacter Pylori Infection

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Osteoarthritis

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Chronic Back Pain

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

prophylaxis of Stress Ulcers

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Heartburn

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Duodenal Ulcer

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Stomach Ulcer

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Warnings

Pepcid Ac Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Pepcid Ac.

Common Pepcid Ac Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The excretion of Abemaciclib can be decreased when combined with Famotidine.

Acenocoumarol

Major

The metabolism of Acenocoumarol can be decreased when combined with Famotidine.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Famotidine.

Anagrelide

Major

The metabolism of Anagrelide can be decreased when combined with Famotidine.

Atazanavir

Major

Famotidine can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.

Pepcid Ac Toxicity & Overdose Risk

The lethal dose of famotidine for rats is 4049mg/kg when taken orally, and 800mg/kg when taken subcutaneously. In humans, the lowest toxic dose is 4mg/kg over 7 days. Symptoms of overdose may include those seen with recommended doses and can be treated with supportive and symptomatic care. Removing any unabsorbed drug from the digestive tract is recommended, and hemodialysis can be used to reduce the amount of the drug in the body.

image of a doctor in a lab doing drug, clinical research

Pepcid Ac Novel Uses: Which Conditions Have a Clinical Trial Featuring Pepcid Ac?

45 active clinical trials are analyzing the potential of Pepcid Ac to alleviate Collagen Diseases, Acid Indigestion and Muscle Spasms.

Condition

Clinical Trials

Trial Phases

Postoperative Pain

19 Actively Recruiting

Phase 4, Phase 2, Phase 1, Phase 3, Not Applicable

Chronic Back Pain

5 Actively Recruiting

Not Applicable

Collagen Diseases

0 Actively Recruiting

Gastric ulcer

0 Actively Recruiting

Critical Illness

0 Actively Recruiting

Gastritis

0 Actively Recruiting

Duodenal Ulcer

0 Actively Recruiting

Zollinger-Ellison Syndrome

0 Actively Recruiting

Curling Ulcer

0 Actively Recruiting

Indigestion

6 Actively Recruiting

Phase 3, Not Applicable, Phase 2

Heartburn

2 Actively Recruiting

Phase 3, Not Applicable

Multiple Endocrine Neoplasia

0 Actively Recruiting

Stress Ulcers

0 Actively Recruiting

Heartburn

0 Actively Recruiting

Spasm

0 Actively Recruiting

Erosive Esophagitis

2 Actively Recruiting

Phase 2, Phase 3

Obesity

0 Actively Recruiting

Pathological Conditions, Anatomical

3 Actively Recruiting

Phase 3, Not Applicable, Phase 2

Osteoarthritis

0 Actively Recruiting

prophylaxis of Stress Ulcers

0 Actively Recruiting

Pepcid Ac Reviews: What are patients saying about Pepcid Ac?

5

Patient Review

12/26/2010

Pepcid Ac for Indigestion

Pepcid AC Complete does a great job at stopping heartburn symptoms. It has an antacid for immediate relief and an H2 blocker for longer term relief, which together last for almost 24 hours. I have found that the only downside to taking it regularly is that I sometimes experience dizziness. This was even bad enough to wake me up from sleep on occasion, but cutting back on the Pepcid AC Complete stopped the problem.

5

Patient Review

9/27/2012

Pepcid Ac for Inflammation of Esophagus from Backflow of Stomach Acid

Pepsid has really been a life-saver for me. I have an allergy to previcid, and it was giving me big problems with acid reflux. My doctor switched me over to pepsid and told me to use it every day. I don't use it every day because I've heard horror stories from friends about the other options out there-- they couldn't get off of them without a lot of pain.

5

Patient Review

10/14/2012

Pepcid Ac for Stomach Ulcer

Not only does Pepcid work quickly to reduce heartburn, but I've also noticed a reduction in my blood pressure. Could this be a contributing factor?

5

Patient Review

5/30/2016

Pepcid Ac for Indigestion

I find Pepcid to be the most effective brand of this type of medicine, providing me with almost instant relief.

5

Patient Review

12/9/2010

Pepcid Ac for Zollinger-Ellison Syndrome

I've been happy with the results of this treatment, but I am concerned that it may be a proton pump inhibitor (PPI). There have been reports of problems with this type of drug. Please advise if Pepcid AC is one of the drugs causing these problems.

5

Patient Review

2/9/2011

Pepcid Ac for Condition in which Stomach Acid is Pushed Into the Esophagus

Pepcid is a godsend for those of us who have had our gall bladders removed. It allows me to eat things I otherwise couldn't without experiencing intense pain later on.

5

Patient Review

8/21/2022

Pepcid Ac for Inflammation of Esophagus from Backflow of Stomach Acid

I was blown away by how quickly this began working. I had zero heartburn or reflux issues the first day, even after eating a spicy meal that night.

5

Patient Review

5/27/2010

Pepcid Ac for Heartburn

This drug works quickly and effectively.

5

Patient Review

2/12/2009

Pepcid Ac for Inflammation of Esophagus from Backflow of Stomach Acid

5

Patient Review

12/16/2009

Pepcid Ac for Stress Ulcer Prevention

I haven't been to the doctor yet, but lately have been experiencing acid indigestion that I think may be acid reflux. I have been taking it when the pain occurs, which takes about 10 minutes to start working. I am definitely going to try to take it in the morning and evening as another reviewer suggested.

4.7

Patient Review

8/13/2009

Pepcid Ac for Condition in which Stomach Acid is Pushed Into the Esophagus

While it's not a perfect solution, this treatment is much better than other options (e.g. taking Alkaseltzer at 3am).

4.7

Patient Review

12/15/2010

Pepcid Ac for Heartburn

I'm very pleased with this treatment.

4.3

Patient Review

12/26/2007

Pepcid Ac for Condition in which Stomach Acid is Pushed Into the Esophagus

4.3

Patient Review

6/9/2009

Pepcid Ac for Prevent Indigestion

I find that I have good results taking two tablets per day. The store brand at Sam's Club is much more affordable than the Pepcid brand or Nexium.

4

Patient Review

6/12/2012

Pepcid Ac for Inflammation of Esophagus from Backflow of Stomach Acid

I was taking Pepcid AC and Protonix for my GERD. They worked great together, but when I had to switch to just Nexium, it stopped working entirely. OTC Pepcid is the way to go from now on.

4

Patient Review

8/24/2016

Pepcid Ac for Heartburn

I've dealt with chronic heartburn for years, and this is the first medication that has really helped. I was originally prescribed Pepcid by the hospital, and it's worked wonders.

3

Patient Review

5/26/2014

Pepcid Ac for Treatment to Prevent Heartburn

I'm still having heartburn and gas after eating certain foods, even though I've only used this medication for a couple days. I remember it working really well last time I took it, so hopefully the effects will kick in soon.

1.7

Patient Review

9/6/2011

Pepcid Ac for Prevent Indigestion

The doctor prescribed Prilosec, but I went back to Pepsid because it's cheaper and works better for me.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about pepcid ac

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does Pepcid AC do to your stomach?

"It works by decreasing the amount of acid your stomach makes. It relieves symptoms of a cough that doesn't go away, stomach pain, heartburn, and difficulty swallowing. Famotidine belongs to a class of drugs known as H2 blockers. This medication is also available without a prescription."

Answered by AI

What are the side effects of Pepcid AC?

"Anxiety, skin problems, bloody stool, difficulty breathing, discouragement, fast heartbeat, feeling sad."

Answered by AI

What is the difference between PEPCID and Pepcid AC?

"There are two types of PEPCID AC; Original Strength and Maximum Strength. They both contain an H2 blocker that begins to work in 15-30 minutes. It helps control acid all day or all night. PEPCID Complete combines an H2 blocker with an antacid that starts neutralizing acid in your stomach in seconds. It works even faster than the other two."

Answered by AI

Is Pepcid AC and Zantac the same thing?

"PEPCID and ZANTAC are approved for the same use, but PEPCID contains Famotidine. ZANTAC contains Ranitidine, which is different from the other over-the-counter products."

Answered by AI

Clinical Trials for Pepcid Ac

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of University Center for Ambulatory Surgery in Somerset, United States.

Infusion Pump for Postoperative Pain

18+
All Sexes
Somerset, NJ

This study will be a pragmatic, prospective cluster randomized trial, where clusters will formed based on sequential 2 week time increments across the study recruitment period.. Patients 18 years or older undergoing ACL reconstruction, open shoulder labrum or rotator cuff surgery, arthroscopic rotator cuff repair, proximal or distal patellar realignment surgery, open knee arthrotomy cases (i.e. inside out meniscus repair, osteochondral allograft transplantation (OCA), meniscal allograft transplantation (MAT)) at University Center for Ambulatory Surgery, LLC (UOA) will be reviewed for eligibility. Once identified, potential study subjects will be asked whether they are interested in participating in the project. If the patient agrees, the subject will be given the informed consent to read and sign. Objectives: The primary objective is to compare the effectiveness of postoperative infusion pain pump versus preoperative nerve block in reducing visual analog pain scores/numerical pain rating scale (VAS/NPRS) in the postoperative period. The second objective is to evaluate the requirement of narcotic and non-narcotic analgesic medications between the two groups. Hypotheses: Use of continuous infusion pain pump or single shot peripheral block will result in similar post-operative pain control after outpatient sports medicine surgical cases.

Phase 4
Recruiting

University Center for Ambulatory Surgery

Have you considered Pepcid Ac clinical trials?

We made a collection of clinical trials featuring Pepcid Ac, we think they might fit your search criteria.
Go to Trials
Image of Public Health Research Center: Clinical Exercise Research Center in Columbia, United States.

Pistachio Snacking for Obesity

25 - 45
All Sexes
Columbia, SC

The purpose of this study is to evaluate the effects of pistachio snacking on metabolic flexibility (at rest, during exercise, and in post-exercise recovery) in healthy overweight and obese adults. Secondary goals include evaluating effects on changes in diet quality, sleep characteristics, physical activity, and hormonal health in women. In randomized order, participants will complete four days of pistachio snacking and four days of normal dietary habits (control). For both conditions, primary outcomes of resting substrate metabolism, metabolic flexibility during exercise, and post-exercise substrate metabolism will be measured pre-post intervention via indirect calorimetry. Secondary outcome of diet quality (kcal, carb, fat, protein) will be measured pre-post intervention via diet log. Exploratory outcomes of daily physical activity (steps, intensity), nightly sleep characteristics (quantity, quality, latency, efficiency), and daytime sleepiness and hunger.

Recruiting
Has No Placebo

Public Health Research Center: Clinical Exercise Research Center

Katie R Hirsch, PhD

Have you considered Pepcid Ac clinical trials?

We made a collection of clinical trials featuring Pepcid Ac, we think they might fit your search criteria.
Go to Trials
Image of Villanova University in Villanova, United States.

BRAVE Intervention for Obesity Stigma

18 - 25
All Sexes
Villanova, PA

This randomized controlled trial will be a curriculum-embedded weight sensitivity training program. There will be two groups. The control group will receive the standard obesity lecture (SOL) and the intervention group will receive the BRAVE Intervention (BRAVE: Building Respect and Acceptance through Valuing Everybody); a Weight Bias Reduction (WBR) intervention. Both groups will have two simulation encounters with standardized patients who are living with obesity and the outcome will be to improve weight bias and increase weight sensitivity over one year. Participants will include second- and fourth-year nursing students. Two cohorts of nursing students will be recruited over two years during orientation for their NUR courses (n = 368); a combined total of 420 students are typically enrolled in these courses. Study participants will be randomized by 8-person simulation groups (clusters) to either the BRAVE intervention or SOL control group. They will then participate in the two simulation-based experiences and weight bias reduction education or standard obesity lecture, respectively, with a debriefing segment and educational components. To compare the efficacy of BRAVE groups to SOL groups in validated questionnaires will assess changing attitudes, beliefs, and clinical communication behaviors when comparing baseline to 3 months post-intervention, and one year after the intervention.

Waitlist Available
Behavior

Villanova University

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of Local Restaurant Site in Bryan, United States.

Menu Labeling for Healthy Habits and Diet

18+
All Sexes
Bryan, TX

This study evaluates the impact of culturally tailored menu labeling interventions on psychosocial factors and ordering behavior among customers in two independently owned Hispanic restaurants in East-Central Texas. Participants will be exposed to one of three sequential menu conditions at each restaurant: (1) a standard menu without nutrition information, (2) a paper menu with bilingual nutrition labels, or (3) a digital menu app enhanced with Augmented Reality (AR) and Artificial Intelligence (AI) providing interactive nutrition guidance. The study will assess whether menu formats influence nutrition literacy, decision-making confidence, self-efficacy, attitudes, behavioral intentions, and actual ordering behavior. Data will be collected through surveys, purchase receipts, and app interaction logs.

Recruiting
Has No Placebo

Local Restaurant Site

Hyunjung Lee, PhD

Have you considered Pepcid Ac clinical trials?

We made a collection of clinical trials featuring Pepcid Ac, we think they might fit your search criteria.
Go to Trials